Gemcitabine in NK/T Cell Lymphoma

NK/T Cell Lymphoma Clinical Trial

Official title:

Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01660568
• Other study ID #: 2012-07-043
• Status: Completed
• Phase: N/A
• First received: August 6, 2012
• Last updated: February 11, 2013
• Start date: August 2012
• Est. completion date: January 2013

Study information

• Verified date: August 2012
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• NK/T cell lymphoma

• relapse or refractory disease

• gemcitabine containing treatment

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• NK/T Cell Lymphoma

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate		2012-May	No